Noticias y eventos de Seer Inc (SEER)SEERSeer Inc

Seer Shareholders Demand Board Member Resignation

Bradley Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, issued an open letter to director Meeta Gulyani, which read, in part, "We respectfully request that you immediately resign from the Company's Board of Directors. You joined the Board despite having no prior public company board experience. When you joined the Seer Board in November of 2021, the Company highlighted the significance of your role at Merck KGaA, but you subsequently left that role in 2023 and no longer work there. When you joined Seer's Board, the Company had a roughly $1.5B market capitalization. Now, its market capitalization is just over $100M. Seer's share price has declined over 90% during your tenure. You have never purchased a single share of the Company despite Seer's shares trading at a discount to net cash. Your lack of public company board experience is currently on full display. You are one of only two Seer directors who potentially have the requisite independence to serve on the Company's Special Committee. The two-member Special Committee that you are part of has refused to adequately explain its purpose or work to stockholders. Your only contribution to our meeting with the two-member Special Committee to discuss our fourth acquisition proposal was to sit quietly and take notes. The only time you spoke was at the very end of the meeting when you were asked whether you had any questions and you said 'no.' We believe you are in way over your head and urge you to immediately step down in the best interests of all Seer stockholders."

Seer Receives Radoff Proposal to Acquire at $2.55 per Share

Seer confirmed that on July 28, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok. or the Radoff-JEC Group, to acquire all of the outstanding shares of Seer's Class A common stock for $2.55 per share in cash plus a contingent value right. On July 29, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, Seer's chair and CEO, to acquire all of the outstanding shares of Seer's Class A common stock for $2.45 per share in cash plus two separate contingent value rights. The previously constituted special committee of Seer's board of directors, in consultation with its advisors, will carefully review and consider both proposals, as well as other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and all Seer stockholders. No stockholder action is required at this time.

Bradley Radoff Proposes Acquisition of Seer at $2.55 per Share

Bradley Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, submitted an improved non-binding proposal to acquire the Company - their fourth such proposal - for $2.55 per share in cash plus a contingent value right. The group said, "We are pleased to submit this further improved, non-binding proposal to acquire 100% of the equity of the Company for $2.55 per share in cash, which represents an immediate 51% premium to the Company's unaffected share price and a 29% premium to the current share price, plus a contingent value right representing the right for stockholders to receive 85% of the net proceeds received from any license, sale or other disposition of Seer's business and assets, including PrognomiQ.We would aim to make all payments under the CVR within six to 12 months of the completion of the Acquisition. To be clear, our offer is not speculative or contingent. Our offer does not undervalue Seer or seek to drain Seer of its cash. In fact, the structure of our proposal is designed to ensure that stockholders receive full and fair value for their investment in Seer by way of a CVR providing the proceeds from an open auction process for the Company's business and assets. We believe our proposal offers stockholders many valuable things that the Board's current strategy does not, including: certainty, accountability and a realistic framework for maximizing remaining value. Furthermore, our proposal does not subject stockholders to continued value destruction under the leadership of Chairman and CEO Omid Farokhzad, M.D. Based upon our analysis, Dr. Farokhzad has destroyed more than $1B in investor capital across Seer, BIND Therapeutics, Selecta Biosciences, Tarveda Therapeutics and Senti Biosciences. We kindly request the Special Committee, and the Board as a whole, to consider Dr. Farokhzad's track record at Seer and across other companies as it evaluates subjecting stockholders to continued losses and cash burn while pursuing his failed strategy. We urge the Special Committee to fulfill its fiduciary obligations by engaging seriously with us regarding our proposal and by providing stockholders with a transparent evaluation process. Entrenchment and continued adherence to a failed operating strategy are not acceptable to stockholders. It is also not an option to accept an inferior buyout offer from Dr. Farokhzad. Our improved offer, which is subject to limited confirmatory due diligence, does not expire until August 10, 2026 - we urge the Special Committee and its independent financial advisor to immediately engage with us and negotiate a transaction that will benefit all stockholders. We are ready to move forward and close expeditiously - once again, our proposal is not subject to any financing conditions."